BlackRock Advisors’s Cidara Therapeutics CDTX Stock Holding History

BlackRock Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$56K	Sell	268 -9	-3%	-$1.87K	﹤0.01%	3227
2016 Q3	$64K	Buy	277 +60	+28%	+$13.9K	﹤0.01%	3179
2016 Q2	$45K	Buy	217 +98	+82%	+$23.7K	﹤0.01%	3249
2016 Q1	$30K	Buy	119 +54	+83%	+$12.4K	﹤0.01%	3324
2015 Q4	$22K	Sell	65 -2,488	-97%	-$747K	﹤0.01%	3463
2015 Q3	$649K	Sell	2,553 -10	-0.4%	-$2.86K	﹤0.01%	1997
2015 Q2	$719K	Buy	+2,563	New	+$788K	﹤0.01%	1900

Other funds holding CDTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Advisors's CDTX Position: Q4 2016 in Review

BlackRock Advisors reduced its Cidara Therapeutics (CDTX) stake by 3.2% in Q4 2016, selling an estimated $1.87K and leaving 268 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #3227.

BlackRock Advisors first reported a position in CDTX in Q2 2015 and has held it in 7 quarters since. The position peaked at $719K in Q2 2015. 58 funds tracked by Wall St. Rank hold CDTX as of Q4 2016.

BlackRock Advisors held 268 shares of Cidara Therapeutics worth $56K as of Q4 2016.
BlackRock Advisors sold 9 Cidara Therapeutics shares in Q4 2016, an estimated $1.87K.
Cidara Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3227 holding.
BlackRock Advisors first reported a position in Cidara Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Advisors's Cidara Therapeutics position peaked at $719K in Q2 2015.
58 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.